BidaskClub upgraded shares of Impax Laboratories (NASDAQ:IPXL) from a sell rating to a hold rating in a research note released on Saturday morning.
Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded Impax Laboratories from a hold rating to a sell rating in a research report on Tuesday, January 2nd. Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the company a buy rating in a research report on Friday, December 15th. Cowen reissued a hold rating and issued a $16.00 target price on shares of Impax Laboratories in a research report on Friday, November 10th. UBS Group upped their target price on Impax Laboratories from $12.00 to $16.00 and gave the company a sell rating in a research report on Monday, October 30th. Finally, Leerink Swann initiated coverage on Impax Laboratories in a research report on Tuesday, January 2nd. They issued an outperform rating and a $22.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $19.62.
Impax Laboratories (NASDAQ IPXL) opened at $20.95 on Friday. The stock has a market capitalization of $1,503.25, a price-to-earnings ratio of -3.35, a PEG ratio of 1.01 and a beta of 1.11. The company has a current ratio of 1.81, a quick ratio of 1.32 and a debt-to-equity ratio of 1.59. Impax Laboratories has a 12-month low of $7.75 and a 12-month high of $25.70.
COPYRIGHT VIOLATION WARNING: “Impax Laboratories (IPXL) Lifted to Hold at BidaskClub” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3224544/impax-laboratories-ipxl-lifted-to-hold-at-bidaskclub.html.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.